RxDoctor Payments Data

Gene Im, MD

Transplant Hepatology · New York, NYNPI 1730497454

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $12,981 of the $14,952 with a category attached, or 86.8%. Novo Nordisk accounts for 95.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $14,480 and has fallen 97.2% since, to $408 in 2025.

$14,952in general payments, 2019–2025

Across 24 payments — averaging $622.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$14K
  • Madrigal Pharmaceuticals$147
  • Cook Medical LLC$139
  • Ipsen Biopharmaceuticals, Inc$133
  • AbbVie$113
  • Gilead$37
  • plus $73 from 3 others

What the payments were for

  • Consulting fees$12,98187%
  • Travel & lodging$1,1438%
  • Food & beverage$8286%

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,952 in reported general payments places this provider in the 80th percentile of 36 transplant hepatology providers in New York.

See all transplant hepatology providers in New York

Medicare billing

Part B allowed, 2024
$32,663
Medicare patients
116
Services billed
263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin29$106,441
TivicayDolutegravir Sodium15$39,929
Tacrolimus142$26,311
VemlidyTenofovir Alafenamide12$16,190
Entecavir13$8,230
Ursodiol47$4,866
Mycophenolate Mofetil22$2,810
Tamsulosin Hcl28$1,134
Pantoprazole Sodium80$932
Lactulose31$657
Spironolactone57$612
Gabapentin64$608
Isosorbide Dinitrate11$450
Atorvastatin Calcium34$396
Oxycodone Hcl24$392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$37$16,19012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 36 transplant hepatology providers in New York.

Other transplant hepatology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →